MA28553B1 - 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine} -3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb - Google Patents

2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine} -3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb

Info

Publication number
MA28553B1
MA28553B1 MA29415A MA29415A MA28553B1 MA 28553 B1 MA28553 B1 MA 28553B1 MA 29415 A MA29415 A MA 29415A MA 29415 A MA29415 A MA 29415A MA 28553 B1 MA28553 B1 MA 28553B1
Authority
MA
Morocco
Prior art keywords
purstic
phenylpyridin
pyrimidin
methylamino
indole
Prior art date
Application number
MA29415A
Other languages
English (en)
French (fr)
Inventor
El-Bdaoui Haddad
Olaf Ritzeler
David J Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA28553B1 publication Critical patent/MA28553B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA29415A 2004-05-12 2006-10-27 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine} -3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb MA28553B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
MA28553B1 true MA28553B1 (fr) 2007-04-03

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29415A MA28553B1 (fr) 2004-05-12 2006-10-27 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine} -3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb

Country Status (23)

Country Link
EP (1) EP1747215A1 (pt)
JP (1) JP2007537266A (pt)
KR (1) KR20070011483A (pt)
CN (1) CN1950359A (pt)
AR (1) AR049274A1 (pt)
AU (1) AU2005245834A1 (pt)
BR (1) BRPI0511029A (pt)
CA (1) CA2566213A1 (pt)
EC (1) ECSP066992A (pt)
GT (1) GT200500111A (pt)
IL (1) IL178992A0 (pt)
MA (1) MA28553B1 (pt)
MX (1) MXPA06012870A (pt)
NO (1) NO20065719L (pt)
PA (1) PA8633101A1 (pt)
PE (1) PE20060269A1 (pt)
RU (1) RU2006143758A (pt)
SV (1) SV2006002111A (pt)
TN (1) TNSN06338A1 (pt)
TW (1) TW200605881A (pt)
UY (1) UY28897A1 (pt)
WO (1) WO2005113544A1 (pt)
ZA (1) ZA200608712B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2563774B1 (en) * 2010-04-27 2014-03-12 Hutchison Medipharma Limited Pyrimidinyl indole compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
PA8633101A1 (es) 2006-01-23
IL178992A0 (en) 2007-03-08
RU2006143758A (ru) 2008-06-27
WO2005113544A1 (en) 2005-12-01
ZA200608712B (en) 2008-06-25
BRPI0511029A (pt) 2007-11-27
UY28897A1 (es) 2005-12-30
PE20060269A1 (es) 2006-05-11
AU2005245834A1 (en) 2005-12-01
ECSP066992A (es) 2006-12-29
TW200605881A (en) 2006-02-16
AR049274A1 (es) 2006-07-12
KR20070011483A (ko) 2007-01-24
MXPA06012870A (es) 2007-02-15
NO20065719L (no) 2006-12-12
JP2007537266A (ja) 2007-12-20
GT200500111A (es) 2006-05-09
CA2566213A1 (en) 2005-12-11
EP1747215A1 (en) 2007-01-31
SV2006002111A (es) 2006-01-30
CN1950359A (zh) 2007-04-18
TNSN06338A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
MA28553B1 (fr) 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine} -3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb
HK1126199A1 (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
EP1954277A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
EP2005957A4 (en) ACID SECRETION INHIBITOR
ZA200806017B (en) Pyrimidine deivatives used as pi-3 kinase inhibitors
ZA200909223B (en) Pyrimidine derivatives useful as raf kinase inhibitors
PL2079727T3 (pl) Inhibitory kinazy
PT2097111E (pt) Heterodímeros de ácido glutámico
ZA200906082B (en) Pyrimidine hydrazide compounds as PGDS inhibitors
IL193653A0 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
IL197777A0 (en) Enantiomerically pure phosphoindoles as hiv inhibitors
PL2057115T3 (pl) 4-Podstawione pochodne kwasu fenoksyfenylooctowego
DK2283024T3 (da) 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
IL198675A0 (en) Novel aminopyrimidine derivatives as plk1 inhibitors
HK1117504A1 (en) Benzimidazole thiophene compounds as plk inhibitors
HUE038975T2 (hu) Foszforsavval stabilizált kreppelõ ragasztó
DK1910267T3 (da) Fremgangsmåde til fremstilling af carboxylsyrealkylestere
IL194549A0 (en) 2-(pyridin-2-yl)-pyrimidines for use as fungicides
IL197327A0 (en) Crystalline rosuvastatin calcium
DK2225198T3 (da) Fremgangsmåde til fremstilling af en substitueret gamma-aminosyre
ZA200709852B (en) Spiro-benzimidazoles as inhibitors of gastric acid secretion
SI2076524T1 (sl) Kiralna fosforjeva spojina
EP2125828A4 (en) THIENOPYRIMIDINVERBINDUNGEN
DK2010538T3 (da) Fremgangsmåde til fremstilling af [(1R), 2S]-2-aminopropionsyre 2-[4-(4-fluor-2-methyl-1H-indol-5-yloxy)-5-methylpyrrol]2,1-f-[1,2,4-triazin-6-yloxy]-1-methylethylester